Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves

Stephen H. McKellar, Stuart Abel, Christopher L. Camp, Rakesh M. Suri, Mark H. Ereth, Hartzell V Schaff

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective: Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart valves. We tested the hypothesis that dabigatran etexilate is as effective as heparin for thromboprophylaxis of mechanical valves in a porcine heterotopic aortic valve model. Methods: Thirty swine underwent implantation of modified bileaflet mechanical valved conduit bypassing the ligated, native descending thoracic aorta. Animals randomly received no anticoagulation (n = 10), enoxaparin 2 mg/kg subcutaneously twice daily (n = 10), or dabigatran etexilate 20 mg/kg orally twice daily. Primary end point was amount of valve thrombus at 30 days. Secondary end points included quantitative measurement of platelet deposition on valve prosthesis, thromboelastography, and hemorrhagic and embolic events. Results: At 30 days, we observed 638 ± 895 mg thrombus in no anticoagulation group, 121 ± 128 mg in enoxaparin group, and 19 ± 31 mg in dabigatran etexilate group (P = .01 enoxaparin vs dabigatran etexilate). Fewer platelets were deposited on valves in dabigatran etexilate group (2.7 × 108) than in enoxaparin group (1.8 × 109, P = .03). No major or occult hemorrhagic or embolic events were observed. By thromboelastographic analysis, dabigatran etexilate produced less prolongation of K value (P = .01) and less decreases in angle (P = .01) and maximum amplitude (P = .001) than enoxaparin. Conclusions: Dabigatran etexilate is as effective as enoxaparin for short-term thromboprophylaxis of mechanical valves. It prevents valve thrombus and platelet deposition at 30 days without increased adverse events. These promising results serve as a foundation for prospective clinical trials with dabigatran etexilate as an alternative to warfarin in patients with bileaflet mechanical aortic valves.

Original languageEnglish (US)
Pages (from-to)1410-1416
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume141
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Heart Valves
Enoxaparin
Thrombosis
Blood Platelets
Warfarin
Thoracic Aorta
Aortic Valve
Swine
Stroke
Thrombelastography
Dabigatran
Antithrombins
Atrial Fibrillation
Prostheses and Implants
Heparin
Clinical Trials
Hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. / McKellar, Stephen H.; Abel, Stuart; Camp, Christopher L.; Suri, Rakesh M.; Ereth, Mark H.; Schaff, Hartzell V.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 141, No. 6, 06.2011, p. 1410-1416.

Research output: Contribution to journalArticle

McKellar, Stephen H. ; Abel, Stuart ; Camp, Christopher L. ; Suri, Rakesh M. ; Ereth, Mark H. ; Schaff, Hartzell V. / Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. In: Journal of Thoracic and Cardiovascular Surgery. 2011 ; Vol. 141, No. 6. pp. 1410-1416.
@article{533bad828d02475a984a66b61ae3c10f,
title = "Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves",
abstract = "Objective: Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart valves. We tested the hypothesis that dabigatran etexilate is as effective as heparin for thromboprophylaxis of mechanical valves in a porcine heterotopic aortic valve model. Methods: Thirty swine underwent implantation of modified bileaflet mechanical valved conduit bypassing the ligated, native descending thoracic aorta. Animals randomly received no anticoagulation (n = 10), enoxaparin 2 mg/kg subcutaneously twice daily (n = 10), or dabigatran etexilate 20 mg/kg orally twice daily. Primary end point was amount of valve thrombus at 30 days. Secondary end points included quantitative measurement of platelet deposition on valve prosthesis, thromboelastography, and hemorrhagic and embolic events. Results: At 30 days, we observed 638 ± 895 mg thrombus in no anticoagulation group, 121 ± 128 mg in enoxaparin group, and 19 ± 31 mg in dabigatran etexilate group (P = .01 enoxaparin vs dabigatran etexilate). Fewer platelets were deposited on valves in dabigatran etexilate group (2.7 × 108) than in enoxaparin group (1.8 × 109, P = .03). No major or occult hemorrhagic or embolic events were observed. By thromboelastographic analysis, dabigatran etexilate produced less prolongation of K value (P = .01) and less decreases in angle (P = .01) and maximum amplitude (P = .001) than enoxaparin. Conclusions: Dabigatran etexilate is as effective as enoxaparin for short-term thromboprophylaxis of mechanical valves. It prevents valve thrombus and platelet deposition at 30 days without increased adverse events. These promising results serve as a foundation for prospective clinical trials with dabigatran etexilate as an alternative to warfarin in patients with bileaflet mechanical aortic valves.",
author = "McKellar, {Stephen H.} and Stuart Abel and Camp, {Christopher L.} and Suri, {Rakesh M.} and Ereth, {Mark H.} and Schaff, {Hartzell V}",
year = "2011",
month = "6",
doi = "10.1016/j.jtcvs.2011.02.011",
language = "English (US)",
volume = "141",
pages = "1410--1416",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves

AU - McKellar, Stephen H.

AU - Abel, Stuart

AU - Camp, Christopher L.

AU - Suri, Rakesh M.

AU - Ereth, Mark H.

AU - Schaff, Hartzell V

PY - 2011/6

Y1 - 2011/6

N2 - Objective: Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart valves. We tested the hypothesis that dabigatran etexilate is as effective as heparin for thromboprophylaxis of mechanical valves in a porcine heterotopic aortic valve model. Methods: Thirty swine underwent implantation of modified bileaflet mechanical valved conduit bypassing the ligated, native descending thoracic aorta. Animals randomly received no anticoagulation (n = 10), enoxaparin 2 mg/kg subcutaneously twice daily (n = 10), or dabigatran etexilate 20 mg/kg orally twice daily. Primary end point was amount of valve thrombus at 30 days. Secondary end points included quantitative measurement of platelet deposition on valve prosthesis, thromboelastography, and hemorrhagic and embolic events. Results: At 30 days, we observed 638 ± 895 mg thrombus in no anticoagulation group, 121 ± 128 mg in enoxaparin group, and 19 ± 31 mg in dabigatran etexilate group (P = .01 enoxaparin vs dabigatran etexilate). Fewer platelets were deposited on valves in dabigatran etexilate group (2.7 × 108) than in enoxaparin group (1.8 × 109, P = .03). No major or occult hemorrhagic or embolic events were observed. By thromboelastographic analysis, dabigatran etexilate produced less prolongation of K value (P = .01) and less decreases in angle (P = .01) and maximum amplitude (P = .001) than enoxaparin. Conclusions: Dabigatran etexilate is as effective as enoxaparin for short-term thromboprophylaxis of mechanical valves. It prevents valve thrombus and platelet deposition at 30 days without increased adverse events. These promising results serve as a foundation for prospective clinical trials with dabigatran etexilate as an alternative to warfarin in patients with bileaflet mechanical aortic valves.

AB - Objective: Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart valves. We tested the hypothesis that dabigatran etexilate is as effective as heparin for thromboprophylaxis of mechanical valves in a porcine heterotopic aortic valve model. Methods: Thirty swine underwent implantation of modified bileaflet mechanical valved conduit bypassing the ligated, native descending thoracic aorta. Animals randomly received no anticoagulation (n = 10), enoxaparin 2 mg/kg subcutaneously twice daily (n = 10), or dabigatran etexilate 20 mg/kg orally twice daily. Primary end point was amount of valve thrombus at 30 days. Secondary end points included quantitative measurement of platelet deposition on valve prosthesis, thromboelastography, and hemorrhagic and embolic events. Results: At 30 days, we observed 638 ± 895 mg thrombus in no anticoagulation group, 121 ± 128 mg in enoxaparin group, and 19 ± 31 mg in dabigatran etexilate group (P = .01 enoxaparin vs dabigatran etexilate). Fewer platelets were deposited on valves in dabigatran etexilate group (2.7 × 108) than in enoxaparin group (1.8 × 109, P = .03). No major or occult hemorrhagic or embolic events were observed. By thromboelastographic analysis, dabigatran etexilate produced less prolongation of K value (P = .01) and less decreases in angle (P = .01) and maximum amplitude (P = .001) than enoxaparin. Conclusions: Dabigatran etexilate is as effective as enoxaparin for short-term thromboprophylaxis of mechanical valves. It prevents valve thrombus and platelet deposition at 30 days without increased adverse events. These promising results serve as a foundation for prospective clinical trials with dabigatran etexilate as an alternative to warfarin in patients with bileaflet mechanical aortic valves.

UR - http://www.scopus.com/inward/record.url?scp=79956087035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956087035&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2011.02.011

DO - 10.1016/j.jtcvs.2011.02.011

M3 - Article

C2 - 21429525

AN - SCOPUS:79956087035

VL - 141

SP - 1410

EP - 1416

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -